2025 Global Autoimmune Disease Treatment Market Revenue Opportunities Report
Description
The 2025 Global Autoimmune Disease Treatment Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global autoimmune disease treatment market are AbbVie, Johnson & Johnson, Sanofi, and F. Hoffmann-La Roche Ltd. AbbVie leads with strong immunology and neuroscience portfolios, including blockbuster drugs like Humira, Skyrizi, and Rinvoq, driving significant revenue despite recent losses of exclusivity. Johnson & Johnson is a key player with a diverse pipeline in pharmaceuticals and medical devices, recently securing Breakthrough Therapy Designation by the FDA for nipocalimab in treating Sjögren’s disease, a novel autoimmune disorder therapy. Sanofi is influential with its growth in immunology, primarily driven by Dupixent, and maintains a broad biopharma innovation focus across rare diseases. Roche is notable in diagnostics and therapeutics, contributing to personalized medicine advancements in autoimmune conditions.
These companies shape the market by pioneering therapies targeting rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other autoimmune disorders, reflecting a growing global demand fueled by rising disease prevalence and enhanced R&D efforts. Their investments in biologics, immunotherapies, and innovative diagnostics underpin market expansion projected to exceed $200 billion by 2030, with these firms holding leading shares. Furthermore, collaborations such as AstraZeneca’s with Quell Therapeutics on engineered T-regulatory cell therapies highlight industry innovation to develop next-generation treatments for autoimmune diseases.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global autoimmune disease treatment market are AbbVie, Johnson & Johnson, Sanofi, and F. Hoffmann-La Roche Ltd. AbbVie leads with strong immunology and neuroscience portfolios, including blockbuster drugs like Humira, Skyrizi, and Rinvoq, driving significant revenue despite recent losses of exclusivity. Johnson & Johnson is a key player with a diverse pipeline in pharmaceuticals and medical devices, recently securing Breakthrough Therapy Designation by the FDA for nipocalimab in treating Sjögren’s disease, a novel autoimmune disorder therapy. Sanofi is influential with its growth in immunology, primarily driven by Dupixent, and maintains a broad biopharma innovation focus across rare diseases. Roche is notable in diagnostics and therapeutics, contributing to personalized medicine advancements in autoimmune conditions.
These companies shape the market by pioneering therapies targeting rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other autoimmune disorders, reflecting a growing global demand fueled by rising disease prevalence and enhanced R&D efforts. Their investments in biologics, immunotherapies, and innovative diagnostics underpin market expansion projected to exceed $200 billion by 2030, with these firms holding leading shares. Furthermore, collaborations such as AstraZeneca’s with Quell Therapeutics on engineered T-regulatory cell therapies highlight industry innovation to develop next-generation treatments for autoimmune diseases.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
